Observational Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 5058-5075
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5058
Table 1 Baseline patient and disease characteristics
Characteristics

N
n (%) or mean ± SD
Age9442.5 (15.3)
GenderMale9456 (59.6)
BMI (kg/m2)9125.4 (4.5)
RaceAmerican Indian/Alaska Native941 (1.1)
Asian5 (5.3)
White88 (93.6)
Employment statusDisability2 (2.1)
Employed (fulltime, part time < 35 h/week)63 (67.0)
Homemaker3 (3.2)
Retired12 (12.8)
Student6 (6.4)
Temporary leave of absence1 (1.1)
Unemployed6 (6.4)
Unknown1 (1.1)
Tobacco useCurrent smoker942 (2.1)
Former smoker34 (36.2)
Never smoked55 (58.5)
Unknown3 (3.2)
Alcohol useNon-drinker9420 (21.3)
Ex-drinker5 (5.3)
Light (less than 2 drinks per day)61 (64.9)
Moderate (2-4 drinks per day)5 (5.3)
Unknown3 (3.2)
Age at UC diagnosis (yr)9834.5 (15.3)
Disease duration (yr)987.9 (8.0)
Family history of UCNo9859 (60.2)
Yes20 (20.4)
Unknown19 (19.4)
Montreal classification of extent of UC E29755 (56.7)
(prior 3 mo)E342 (43.3)
Mayo Endoscopic Subscore 1901 (1.1)
(prior 3 mo)266 (73.3)
323 (25.6)
Endoscopy (prior 6 mo)Yes9891 (92.9)
UC-related ED visit (prior 6 mo)Yes9813 (13.3)
UC-related hospitalization (prior 6 mo)Yes9812 (12.2)
Previous biologic useYes445 (11.4)
Medication use:Corticosteroids9863 (64.3)
Since UC diagnosis to prior 6 moImuran (azathioprine)37 (37.8)
6-MP8 (8.2)
5-ASA83 (84.7)
Methotrexate5 (5.1)
Cyclosporine1 (1.0)
Medication use: Corticosteroids9861 (62.2)
Since prior 6 mo to currentImuran (azathioprine)39 (39.8)
6-MP5 (5.1)
5-ASA67 (68.4)
Methotrexate8 (8.2)
Cyclosporine0 (0.0)